Other research analysts have also issued research reports about the stock. BidaskClub lowered shares of Loxo Oncology from a hold rating to a sell rating in a research note on Friday, August 4th. BTIG Research restated a buy rating and set a $75.00 price target on shares of Loxo Oncology in a research note on Thursday, August 3rd. Zacks Investment Research lowered shares of Loxo Oncology from a buy rating to a hold rating in a research note on Saturday, August 12th. Stifel Nicolaus restated a buy rating and set a $94.00 price target (up previously from $71.00) on shares of Loxo Oncology in a research note on Thursday, August 10th. Finally, JMP Securities lowered shares of Loxo Oncology from an outperform rating to a market perform rating and cut their price target for the company from $83.12 to $17.14 in a research note on Tuesday, August 29th. They noted that the move was a valuation call. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The stock has an average rating of Buy and an average target price of $90.57.

Shares of Loxo Oncology (LOXO) traded up $3.13 during trading on Tuesday, reaching $76.75. 390,500 shares of the company’s stock were exchanged, compared to its average volume of 370,814. Loxo Oncology has a twelve month low of $25.25 and a twelve month high of $95.92.

In other news, Director Orbimed Advisors Llc sold 270,000 shares of the stock in a transaction on Thursday, November 16th. The shares were sold at an average price of $74.26, for a total value of $20,050,200.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, major shareholder Aisling Capital Iii Lp sold 500,000 shares of the stock in a transaction on Wednesday, November 22nd. The stock was sold at an average price of $75.00, for a total transaction of $37,500,000.00. The disclosure for this sale can be found here. Insiders sold 1,123,596 shares of company stock worth $84,872,356 in the last quarter. Company insiders own 27.80% of the company’s stock.

Large investors have recently added to or reduced their stakes in the company. FMR LLC boosted its holdings in Loxo Oncology by 12.1% during the second quarter. FMR LLC now owns 4,394,827 shares of the biopharmaceutical company’s stock worth $352,420,000 after buying an additional 472,814 shares in the last quarter. BlackRock Inc. boosted its holdings in Loxo Oncology by 20.6% during the second quarter. BlackRock Inc. now owns 1,602,885 shares of the biopharmaceutical company’s stock worth $128,534,000 after buying an additional 273,291 shares in the last quarter. Alliancebernstein L.P. boosted its holdings in Loxo Oncology by 50.2% during the second quarter. Alliancebernstein L.P. now owns 936,790 shares of the biopharmaceutical company’s stock worth $75,121,000 after buying an additional 312,988 shares in the last quarter. Vanguard Group Inc. boosted its holdings in Loxo Oncology by 24.7% during the second quarter. Vanguard Group Inc. now owns 914,719 shares of the biopharmaceutical company’s stock worth $73,351,000 after buying an additional 181,471 shares in the last quarter. Finally, Lord Abbett & CO. LLC boosted its holdings in Loxo Oncology by 372.0% during the second quarter. Lord Abbett & CO. LLC now owns 739,540 shares of the biopharmaceutical company’s stock worth $59,304,000 after buying an additional 582,862 shares in the last quarter.

TRADEMARK VIOLATION WARNING: This piece was first posted by Watch List News and is the property of of Watch List News. If you are viewing this piece on another publication, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark legislation. The original version of this piece can be viewed at https://www.watchlistnews.com/william-blair-begins-coverage-on-loxo-oncology-loxo/1737230.html.

Loxo Oncology Company Profile

Loxo Oncology, Inc is a biopharmaceutical company. The Company is focused on development of medicines for patients with genetically defined cancers. The Company’s pipeline focuses on cancers that are dependent on single gene abnormalities, such that a single drug has the potential to treat the cancer with dramatic effect.